How to keep muscle while losing weight on Ozempic or Mounjaro

Roughly a quarter to 40% of the weight you drop on a GLP-1 is lean (fat-free) mass, not fat. That sounds alarming. The detail matters more than the headline number.

In the STEP 1 substudy (Wilding et al., 2021), people on semaglutide 2.4 mg scanned with DXA lost a lot of fat: total fat mass fell 19.3% and visceral fat 27.4% over 68 weeks. Lean body mass dropped 9.7%. So on semaglutide, lean mass made up close to 40% of the total weight lost. For tirzepatide, the SURMOUNT-1 substudy (Look et al., 2025) showed a smaller share: at 72 weeks fat mass fell 33.9% (about 15.9 kg) and lean mass 10.9% (about 5.6 kg), so roughly 74 to 75% of the loss was fat and 25 to 26% lean.

Here is the part the scary headlines skip. "Lean" or "fat-free" mass on a DXA scan is not the same as muscle. It includes water, glycogen, bone and organ tissue. So kilograms of lean-mass loss overstate the actual muscle you lose. Do not read the two as equal.

And your overall body composition can improve even while absolute lean mass falls. In STEP 1, lean mass as a proportion of total body mass rose by 3.0 percentage points, and the lean-to-fat ratio improved (more so in people who lost at least 15% of their weight). Tirzepatide drove far larger fat loss than lean loss, so the body composition shift was even more favourable.

One more reassurance from the data. In SURMOUNT-1, that 25% lean fraction of weight lost was essentially identical in the placebo group. Translation: GLP-1s are not uniquely catabolic (muscle-wasting). Lean-mass loss tags along with basically all rapid weight loss, whether from dieting, surgery or these drugs. The real question is magnitude and speed, especially if you are older.

Some lean-mass loss is normal, expected, and not automatically harmful. The fat you lose buys real metabolic benefit. What actually matters for your future is muscle function and strength, not a single number on a DXA report.

Why does that distinction count? Because strength and mass do not move in lockstep over the short term. In the SEMALEAN study (Alissou et al., 2025), people on semaglutide lost about 3.0 kg of lean mass by month 7, then it stabilized through month 12. Yet handgrip strength went up by 4.1 kg, and the share of people with sarcopenic obesity (low muscle plus high fat) fell from 49% to 33%. So they got lighter, lost some lean tissue on paper, and got stronger. That is the pattern you want.

Now the honest counter-signal, because pretending it does not exist would be selling you something. In older adults with type 2 diabetes, longer-term semaglutide use has been linked to handgrip decline and faster sarcopenia (Prokopidis et al., 2026). The same work makes a key point: lean-mass loss is not a reliable predictor of strength change. You cannot read a DXA number and know what happened to function, in either direction.

So who needs the most caution?

• Older adults, where muscle reserve is already thinner.
• Frail patients or anyone at sarcopenia risk before starting.
• People losing weight fast, since speed and magnitude amplify the concern.
• Bone matters too, and rapid loss can affect it, so it belongs on the watch list.

The takeaway is not "avoid these drugs." It is that the scale and the DXA printout do not tell you whether you are getting frailer or fitter. Strength does. If you are 40-plus and especially if you are 65-plus, treat strength and function as the real outcome to protect, then use the next two sections to actually protect it.

Resistance (strength) training two to three times a week is the single most evidence-based way to hold onto muscle while you lose weight. It does three things at once: it protects fat-free mass, it pushes loss further toward fat, and it makes you meaningfully stronger.

The best summary number comes from a 2025 meta-analysis (Binmahfoz et al.) pooling 25 randomised trials with 1,608 people. Comparing strength training during weight loss against dieting alone, the results were clear:

• Fat-free mass: standardised effect +0.40 (95% CI 0.18 to 0.61), meaning more muscle preserved.
• Fat mass: standardised effect -0.36 (95% CI -0.49 to -0.23), so more fat lost.
• Strength: standardised effect +2.36, a large jump in how strong people got.

That is a rare trio: you keep more muscle, lose more fat, and get stronger, all from the same habit. Caloric-restriction work in older adults points the same way (Sardeli et al., 2018; Villareal et al., 2017, an NEJM trial in dieting obese older adults).

Now the honest caveat, because it changes how you should read this. None of these trials tested strength training layered specifically onto semaglutide or tirzepatide. The evidence comes from diet-based and general weight-loss studies. The biology is the same, the recommendation is sound, but a large GLP-1-specific exercise RCT has not reported yet. So treat this as best-available and mechanistically solid, not as proven inside the exact drug context.

What to actually do? Keep it boring and repeatable.

1. Two to three full-body strength sessions per week. That is the dose backed by the data, not five.
2. Cover the big movements: a squat or leg press, a push, a pull, a hinge.
3. Add a little load or a rep when a set starts to feel easy. Progression is the active ingredient.
4. You do not need a fancy gym. Bands, dumbbells, or bodyweight all count if you make them hard enough.

Walking is great for your heart, but it will not preserve muscle on its own. The lifting is the part that protects you here.

Eat more protein than you used to, especially while you are actively losing weight. The practical target for at-risk and older adults is roughly 1.2 to 1.5 g of protein per kg of body weight per day, and weight-loss practice often aims toward the upper end (around 1.5 g/kg of your target weight).

Those numbers come from two big consensus papers, both DACH-relevant: PROT-AGE (Bauer et al., 2013) and the ESPEN expert group (Deutz et al., 2014). They set 1.0 to 1.2 g/kg/day as a healthy-older-adult baseline and bump it to 1.2 to 1.5 g/kg when someone is ill or at risk. Important honesty: these targets were written for aging and general weight loss, then extrapolated to GLP-1 users. They have not been tested head-to-head in semaglutide or tirzepatide trials.

How you eat protein matters as much as how much. The consensus advice is to spread it out: aim for about 25 to 30 g of high-quality protein per meal, across the day, and pair it with your strength training. Protein plus lifting beats either one alone for holding muscle. Higher-protein, energy-restricted diets also help preserve fat-free mass during weight loss (Wycherley et al., 2012).

Here is the real-world problem nobody warns you about. GLP-1 drugs work by killing your appetite. That is the point. But it also means hitting a protein target gets genuinely hard, because three small bites in you feel full. Protein will not happen by accident on these drugs. You have to build meals around it on purpose.

A few practical moves:

• Eat the protein first, before the carbs and veg, while your appetite still cooperates.
• Front-load it earlier in the day when nausea tends to be milder.
• Keep easy options ready: skyr, quark, eggs, Magerquark, tuna, a protein shake.
• If a full meal feels impossible, a 25 g protein snack still counts toward the daily total.

Think of protein as the food job and lifting as the movement job. Together they are what keep the weight you lose mostly fat.

Track strength and function, not just the number on the scale. The German shorthand is "Funktion vor Waage": function before the scale. A lighter, stronger you is the win, and the bathroom scale cannot tell you which is happening.

Why not just weigh yourself? Because the scale lumps fat, muscle, water and food together. You can lose 8 kg and be fitter, or lose 8 kg and be frailer, and the scale reads the same. Strength and function are what separate the two.

The good news for DACH readers is that the useful tools are cheap and accessible:

• Handgrip dynamometry. A simple grip test, available in many practices and gyms, that tracks overall strength surprisingly well. SEMALEAN used exactly this measure.
• Bioimpedance (BIA). The body-composition scales found in many gyms and pharmacies. Not as precise as DXA, but fine for tracking your own trend over months.
• Chair-stand test. Stand up from a chair and sit back down as many times as you can in 30 seconds, or time five reps. Free, repeatable at home, and a solid proxy for leg strength and function.

DXA gives the most precise body-composition read, splitting fat, lean and bone. The catch in DACH is access and cost: DXA for body composition is more limited and usually self-pay. If you can get a baseline scan and one follow-up, it gives a clean before-and-after picture, but you do not need it to monitor well.

The trick is to watch trends over months, not single snapshots. Short-term DXA lean-mass numbers can overstate functional harm, since strength often holds or improves even as lean mass dips (SEMALEAN). And in frail older adults, a reassuring DXA number can understate longer-term risk (Prokopidis et al., 2026). So pick one strength test, one function test, retest every couple of months, and trust the direction of the line. If your grip and chair-stand are steady or improving while the weight drops, you are doing this right.

A muscle-sparing combination is in the pipeline, and the early data look striking, but it is not available yet. Bimagrumab, an antibody that blocks the activin type II receptor (a brake-release for muscle), was tested alongside semaglutide in the phase 2 BELIEVE trial (Heymsfield, Aronne et al., 2026), with 507 participants.

The result that got attention: high-dose bimagrumab plus semaglutide produced about 22% weight loss at 72 weeks, with around 92% of that loss coming from fat and only about 2.9% from lean mass. Compare that to semaglutide alone in the same trial: about 15.7% weight loss, roughly 75.6% fat and 7.4% lean reduction. So the combination lost more weight and protected far more muscle.

Now the brakes. BELIEVE is phase 2 and investigational. Bimagrumab is not approved and not standard care, and it has its own side-effect profile, still being characterised in trials. Treat it as a promising future option, not something to ask for next month.

For now, the real-world levers in DACH are still lifting, protein and monitoring. Which brings us to money, because cost shapes everyone's plan here.

In Germany, Wegovy (semaglutide) and Mounjaro (tirzepatide) for weight loss are not reimbursed. They are classed as Lifestyle-Arzneimittel under § 34 SGB V, so statutory insurance (GKV) will not pay. You need a Privatrezept and you pay out of pocket. Rough 2025/26 self-pay figures:

• Wegovy: about EUR 170 to 270 per month.
• Mounjaro: about EUR 206 to 482 per month, depending on dose.

Only the diabetes indications (for example Ozempic, or Mounjaro for type 2 diabetes) may be covered. Austria and Switzerland mirror this self-pay reality for obesity.

One caveat on the prices. They are dose-dependent, they fluctuate, and supply has been patchy. These figures come from pharmacy and telehealth price lists, so check a current Lauer-Taxe or pharmacy quote before you budget on a specific number.